GenePOC grabs funding from Emerillon Capital and Debiopharm Diagnostics
Canadian venture capital firm Emerillon Capital and Debiopharm Diagnostics, a subsidiary of Swiss biopharmaceutical conglomerate Debiopharm Group, have led a financing round for GenePOC Inc. The round's financial terms were disclosed. Based in Québec City, GenePOC is a developer of molecular devices to detect genes at point-of-care. The technology supports the early diagnosis and prevention of infectious diseases. Update: GenePOC was founded in 2007 by Dr. Michel G. Bergeron. Emerillon was established in 2013 through a partnership between Groupe Crédit Mutuel – CIC and Mouvement Desjardins.
13 January 2015•3 mins read
